Joint Ventures Recaps Influential EULAR Studies in SLE, RA, and More
Episode 2 · Jul 16, 09:00 PM
Share
Subscribe
In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD (academic clinical lecturer in rheumatology, University of Leeds), and Rihards Buss, MD (consultant rheumatologist, Freeman Hospital, Newcastle), record a post-EULAR 2026 debrief, working through the abstracts each identified as the meeting's most consequential. The conversation spans cellular therapies in autoimmune disease, proteomic biomarkers for treatment selection in RA, a landmark head-to-head trial in psoriatic arthritis, evolving classification criteria for axial spondyloarthritis, and the first phase III randomized controlled trial of a JAK inhibitor in polymyalgia rheumatica.
Studies featured in this episode include:
- AB-101 Allogeneic NK Cell Therapy in Rheumatologic Diseases (LB0003)
- CARLYSLE: Obe-Cel CAR T in Severe Refractory SLE (OP0341)
- Ex Vivo Proteomic Signatures of JAK and TNF Inhibitors Predict Treatment Response in RA (OP048)
- BE BOLD: Bimekizumab vs Risankizumab in PsA (LB0001)
- 2025 ASAS-SPARTAN Revised AxSpA Classification Criteria (OP0236, OP0239, POS0190, POS1341)
- JAK-SPARE: Baricitinib in Early Polymyalgia Rheumatica (LB0005)